

SABCS: Updated analysis confirms endocrine therapy effective with/without chemo

December 12 2022, by Elana Gotkine



For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative early breast cancer (EBC) with a 21-gene recurrence score (RS) of 11 to 25, adjuvant endocrine therapy (ET) is noninferior to chemotherapy plus ET (CET) during follow-up exceeding 10 years, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 6 to 10 in San Antonio.

Joseph Sparano, M.D., from Mount Sinai Health System in New York City, and colleagues reported an updated analysis of a trial involving [women](#) aged 18 to 75 years with HR-positive, HER2-negative T1b-T2N0 EBC who agreed to be randomly assigned to adjuvant ET or CET based on the RS assay. Invasive disease-free survival (iDFS) in the RS 11 to 25 group was assessed as the primary end point. The updated analysis was performed after a median follow-up exceeding 10 years.

The researchers found that the conclusions of the primary trial after a median of 7.5 years remained unchanged in the updated analysis: In the randomly assigned group with RS of 11 to 25, ET was noninferior to CET. For an RS of 0 to 25, recurrence occurred in

Citation: SABCS: Updated analysis confirms endocrine therapy effective with/without chemo (2022, December 12) retrieved 11 May 2024 from <https://medicalxpress.com/news/2022-12-sabcs-analysis-endocrine-therapy-effective.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.